MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Quack, M.
Right arrow Articles by Carlberg, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Quack, M.
Right arrow Articles by Carlberg, C.

Vol. 55, Issue 6, 1077-1087, June 1999

Selective Recognition of Vitamin D Receptor Conformations Mediates Promoter Selectivity of Vitamin D Analogs

Marcus Quack and Carsten Carlberg

Institut für Physiologische Chemie I, Heinrich-Heine-Universität, Düsseldorf, Germany

The transcription factor VDR is the nuclear receptor for 1alpha ,25-dihydroxyvitamin D3 (VD) and the mediator of all genomic actions of the nuclear hormone and its synthetic analogs. The sharp biological profile of the model VD analog 1(S),3(R)-dihydroxy-20(R)-(5'-ethyl-5'-hydroxy-hepta-1'(E),3'(E)-dien-1'-yl)-9,10-secopregna-5(Z),7(E),10(19)-triene (EB1089) (i.e., its high antiproliferative effect combined with low calcemic actions) has been correlated with the selectivity of EB1089 to activate heterodimeric complexes of VDR with its partner retinoid X receptor (RXR) on VD response elements (VDREs). These VDREs are formed by an inverted palindromic arrangement of two hexameric core binding motifs spaced by nine nucleotides (IP9) rather than VDREs that are formed by direct repeats with three intervening nucleotides (DR3). In this report, ligand-dependent gel-shift assays were used for a comparison of the ability of VD and EB1089 to stabilize VDR-RXR heterodimers on these two VDRE types. The gel-shift assays revealed EB1089 to be more sensitive for complexes on IP9-type VDREs than on DR3-type VDREs. In addition, a gel-shift clipping method was established to identify and compare complexes of ligand-stabilized VDR-RXR heterodimers on different VDREs. On each VDRE, two complexes could be discriminated that seemed to contain different functional conformations of the VDR and allowed a more differential view on DNA-complexed VDR-RXR heterodimers. The VDR-RXR conformation (which was more ligand-sensitive) gained through EB1089 a higher affinity (7-fold) for DNA binding and a more sensitive (9-fold) activation of an IP9-type VDRE than of a DR3-type VDRE, whereas with the natural hormone VD, no VDRE-type preference could be observed. This indicates that promoter selectivity of VDR ligands is based on their property to selectively increase affinity for VDREs and very sensitively stabilize VDR conformations in VDR-RXR-VDRE complexes.

Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
F. Molnar, M. Perakyla, and C. Carlberg
Vitamin D Receptor Agonists Specifically Modulate the Volume of the Ligand-binding Pocket
J. Biol. Chem., April 14, 2006; 281(15): 10516 - 10526.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. Perakyla, M. Malinen, K.-H. Herzig, and C. Carlberg
Gene Regulatory Potential of Nonsteroidal Vitamin D Receptor Ligands
Mol. Endocrinol., August 1, 2005; 19(8): 2060 - 2073.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
J.-N. Bastie, N. Balitrand, F. Guidez, I. Guillemot, J. Larghero, C. Calabresse, C. Chomienne, and L. Delva
1{alpha},25-Dihydroxyvitamin D3 Transrepresses Retinoic Acid Transcriptional Activity via Vitamin D Receptor in Myeloid Cells
Mol. Endocrinol., November 1, 2004; 18(11): 2685 - 2699.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. J. Bernardi, D. L. Trump, W.-D. Yu, T. F. McGuire, P. A. Hershberger, and C. S. Johnson
Combination of 1{alpha},25-Dihydroxyvitamin D3 with Dexamethasone Enhances Cell Cycle Arrest and Apoptosis: Role of Nuclear Receptor Cross-Talk and Erk/Akt Signaling
Clin. Cancer Res., December 1, 2001; 7(12): 4164 - 4173.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. L. FINCH, A. S. DUSSO, T. PAVLOPOULOS, and E. A. SLATOPOLSKY
Relative Potencies of 1,25-(OH)2D3 and 19-Nor-1,25-(OH)2D2 on Inducing Differentiation and Markers of Bone Formation in MG-63 Cells
J. Am. Soc. Nephrol., July 1, 2001; 12(7): 1468 - 1474.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
A. J. BROWN, J. FINCH, F. TAKAHASHI, and E. SLATOPOLSKY
Calcemic Activity of 19-Nor-1,25(OH)2D2 Decreases with Duration of Treatment
J. Am. Soc. Nephrol., November 1, 2000; 11(11): 2088 - 2094.
[Abstract] [Full Text]

Home page
 J. Am. Soc. Nephrol.Home page
L. S. HOLLIDAY, S. L. GLUCK, E. SLATOPOLSKY, and A. J. BROWN
1,25-Dihydroxy-19-nor-vitamin D2, a Vitamin D Analog with Reduced Bone Resorbing Activity In Vitro
J. Am. Soc. Nephrol., October 1, 2000; 11(10): 1857 - 1864.
[Abstract] [Full Text]

Home page
 Nucleic Acids ResHome page
S. Kronenberg, C. Esser, and C. Carlberg
An aryl hydrocarbon receptor conformation acts as the functional core of nuclear dioxin signaling
Nucleic Acids Res., June 15, 2000; 28(12): 2286 - 2291.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Herdick, Y. Bury, M. Quack, M. R. Uskokovic, P. Polly, and C. Carlberg
Response Element and Coactivator-Mediated Conformational Change of the Vitamin D3 Receptor Permits Sensitive Interaction with Agonists
Mol. Pharmacol., June 1, 2000; 57(6): 1206 - 1217.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.Home page
M. Quack and C. Carlberg
The Impact of Functional Vitamin D3 Receptor Conformations on DNA-Dependent Vitamin D3 Signaling
Mol. Pharmacol., February 1, 2000; 57(2): 375 - 384.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics